Research Institute Havelhöhe, 14089 Berlin, Germany.
Research Institute Havelhöhe, 14089 Berlin, Germany; Oncological Centre, Hospital Gemeinschaftskrankenhaus Havelhöhe, 14089 Berlin, Germany.
Complement Ther Med. 2018 Oct;40:151-157. doi: 10.1016/j.ctim.2018.03.012. Epub 2018 Apr 4.
The concept of integrative oncology (IO) comprising guideline-oriented standard and add-on complementary medicine has gained growing importance. The Anthroposophic-integrative Cancer Centre (CC) at the hospital Gemeinschaftskrankenhaus (GKH) in Berlin has been implementing IO concepts during recent years. Furthermore, it is a certified CC and has been annually audited by national cancer authorities since 2012. The objective of the present study was to evaluate IO concepts of the certified CC GKH.
Clinical, demographic, integrative treatment and follow-up data were analyzed between 2011 and 2016. In addition, CC GKH quality measures were compared with those of nationwide benchmarking CCs.
Between 2011 and 2016, 2.382 primary cancer patients, median age 66 years, were treated at the CC GKH. 70.1% of the patients showed either Union for International Cancer Control (UICC) stage 0, I, II or III and 25.6% were in UICC stage IV. IO therapies included surgery (64.4% of patients), radiation (41.2%), and application of cytostatic drugs (53.9%), add-on mistletoe therapy (30.5%), and non-pharmacological interventions (87.3%). Regarding psycho-oncological support and quota of patient's enrollment in studies the CC GKH performs above nationwide benchmarks. Research outcomes including safety issues, clinical impact as well as patient's health-related quality of life are continuously evaluated and integrated into hospital's decision-management.
This analysis reveals that IO concepts are applied to a high proportion of male and female primary cancer patients of all age groups, indicating a successful implementation at the certified CC GKH. Ongoing clinical evaluations have been initiated and cost-effectiveness comparisons are under analyses.
包含以指南为导向的标准和补充补充医学的综合肿瘤学（IO）概念变得越来越重要。柏林 Gemeinschaftskrankenhaus（GKH）医院的人智学综合癌症中心（CC）近年来一直在实施 IO 概念。此外，它是一个经过认证的 CC，并自 2012 年以来每年由国家癌症机构进行审核。本研究的目的是评估经过认证的 GKH CC 的 IO 概念。
分析了 2011 年至 2016 年的临床，人口统计学，综合治疗和随访数据。此外，还将 CC GKH 的质量指标与全国基准 CC 的质量指标进行了比较。
2011 年至 2016 年间，有 2382 名原发性癌症患者在 CC GKH 接受治疗，中位年龄为 66 岁。70.1％的患者处于 Union for International Cancer Control（UICC）0、I、II 或 III 期，25.6％处于 UICC 期 IV。IO 疗法包括手术（64.4％的患者），放射治疗（41.2％）和细胞毒药物应用（53.9％），附加槲寄生疗法（30.5％）和非药物干预（87.3％）。就心理肿瘤学支持和患者入组研究的配额而言，CC GKH 的表现优于全国基准。正在不断评估研究结果，包括安全性问题，临床影响以及患者的健康相关生活质量，并将其纳入医院的决策管理中。
这项分析表明，IO 概念适用于各个年龄段的男女原发性癌症患者中的很大一部分，表明经过认证的 CC GKH 成功实施了这些概念。已经启动了持续的临床评估，并正在分析成本效益比较。
